- $36.20m
- $78.68m
- $22.77m
- 46
- 45
- 37
- 38
Annual income statement for Celularity, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 21.3 | 18 | 22.8 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 11.7 | -1.69 | 6.75 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.564 | 4.22 | 130 | 43.6 | 215 |
| Operating Profit | -0.564 | -4.22 | -109 | -25.6 | -192 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 3.18 | -2.44 | -100 | 14.2 | -196 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 2.51 | -2.63 | -100 | 14.2 | -196 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 2.51 | -2.63 | -100 | 14.2 | -196 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 2.51 | -2.63 | -100 | 14.2 | -196 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 3.14 | -3.03 | -14.9 | 1.19 | -2.99 |